Evidence map›Paper›PMID 39852777›Full record

ReviewNeurology international2025

Optical Coherence Tomography in Huntington's Disease-A Potential Future Biomarker for Neurodegeneration?

Clancy Cerejo, Nicolas De Cleene, Elias Mandler, Katarina Schwarzová, Samuel Labrecque, Philipp Mahlknecht, Florian Krismer, Atbin Djamshidian, Klaus Seppi, Beatrice Heim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clancy CerejoDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Nicolas De CleeneDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Elias MandlerDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Katarina SchwarzováDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Samuel LabrecqueDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.ORCID 0009-0006-9109-6205
Philipp MahlknechtDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0003-0671-0516
Florian KrismerDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Atbin DjamshidianDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Klaus SeppiDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.
Beatrice HeimDepartment of Neurology, Medical University of Innsbruck, Innsbruck 6020, Austria.ORCID 0000-0002-6749-3044

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder for which, until now, only symptomatic treatment has been available. Lately, there have been multiple ongoing clinical trials targeting therapeutic agents for preventing disease onset or slowing disease progression in HD. These studies are in constant need of reliable biomarkers for neurodegeneration in HD. In recent years, retinal biomarkers have attracted significant attention in neurodegenerative disorders. Likewise, optical coherence tomography (OCT) is being evaluated as a potential biomarker in HD. In this article, we review the existing literature on OCT as a biomarker for neurodegeneration in HD.

Indexed as

Huntington's diseaseneurodegenerationoptical coherence tomography

Identifiers

PMID39852777
PMCPMC11767877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.